ERBB2 and non-small cell lung carcinoma: The standard first-line treatment for advanced NSCLC with HER2 alterations, immune checkpoint inhibitor (ICI) therapy, has shown limited clinical activity with an objective response rate (ORR) ranging from 7.4% to 27.3% and median progression-free survival (mPFS) ranging from 1.9 to 2.5 months (7).